Seroprevalence of SARS-CoV-2 antibodies prior to the widespread introduction of vaccine programmes in the WHO European Region, January - December 2020: a systematic review

A Vaughan, EF Duffell, GS Friedl, DS Lemos, T Funk, A Nardone, M Valenciano, L Subissi, I Bergeri, E Broberg, P Penttinen, R Pebody, M Keramarou
doi: https://doi.org/10.1101/2021.12.02.21266897

Article usage

Article usage: December 2021 to August 2025

AbstractFullPdf
Dec 202164515129
Jan 2022571714
Feb 20221021622
Mar 2022571216
Apr 202243418
May 202244819
Jun 20223858
Jul 202255717
Aug 20222935
Sep 20223575
Oct 202235210
Nov 20223135
Dec 202219610
Jan 20232957
Feb 20232726
Mar 202319113
Apr 20232286
May 20231468
Jun 20231053
Jul 20231112
Aug 202316127
Sep 20231888
Oct 20231136
Nov 202321133
Dec 20231405
Jan 20241059
Feb 20241275
Mar 202414812
Apr 202410511
May 20241247
Jun 20241153
Jul 202417312
Aug 20242254
Sep 202427616
Oct 20241787
Nov 20242538
Dec 20241655
Jan 20251619
Feb 202517464
Mar 202543447
Apr 202526418
May 202523456
Jun 2025382511
Jul 2025293019
Aug 2025237
Back to top
Posted December 05, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Seroprevalence of SARS-CoV-2 antibodies prior to the widespread introduction of vaccine programmes in the WHO European Region, January - December 2020: a systematic review
A Vaughan, EF Duffell, GS Friedl, DS Lemos, T Funk, A Nardone, M Valenciano, L Subissi, I Bergeri, E Broberg, P Penttinen, R Pebody, M Keramarou
medRxiv 2021.12.02.21266897; doi: https://doi.org/10.1101/2021.12.02.21266897
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area